Sareum Holdings plc (LON:SAR – Get Free Report) shares crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of GBX 29.47 and traded as low as GBX 27. Sareum shares last traded at GBX 27.50, with a volume of 1,142,724 shares changing hands.
Sareum Stock Performance
The business has a 50-day simple moving average of GBX 29.71 and a two-hundred day simple moving average of GBX 23.93. The company has a market capitalization of £38.07 million, a price-to-earnings ratio of -6.99 and a beta of -1.08.
Sareum Company Profile
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Further Reading
- Five stocks we like better than Sareum
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
